select a format

Single User License
USD 250 INR 16198
Site License
USD 500 INR 32395
Corporate User License
USD 750 INR 48593

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Perrigo Company Plc (PRGO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Perrigo Company Plc (PRGO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH4204D
  • |
  • Pages: 136
  • |
  • July 2017
  • |
  • |
  Request for Sample Report

Executive Summary

Summary

Perrigo Company plc (Perrigo) is an over-the-counter consumer goods and specialty pharmaceutical company. It develops, manufactures and distributes over-the-counter products, generic and prescription pharmaceuticals, specialty pharmaceutical company, nutritional products, active pharmaceutical ingredients (APIs) and infant formulas. The company's major products include analgesics, gastrointestinal, personal care and derma therapeutics, colobetasol spray, clindamycin foam, mupirocin ointment, halobetasol ointment and cream and permethrin cream. It markets products through wholesalers, retail drug, supermarket and mass merchandise chains and direct sales representatives. The company has operations in North America, Europe, Australia and other countries including Israel and China. Perrigo is headquartered in Dublin, Ireland.

Perrigo Company Plc (PRGO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 7

Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8

Perrigo Company Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9

Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10

Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 11

Perrigo Company Plc, Medical Devices Deals, 2011 to YTD 2017 13

Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 14

Perrigo Company Plc, Pharmaceuticals & Healthcare, Deal Details 19

Asset Purchase 19

Perrigo Acquires Generic Dosage Forms of Retin-A from Matawan Pharma 19

Perrigo Acquires US Rights to Entocort from AstraZeneca for USD380 Million 19

Perrigo Acquires ScarAway Brand from Enaltus 20

Perrigo Acquires OTC Brands Portfolio from GlaxoSmithKline Consumer Healthcare for USD226 Million 21

Perrigo Acquires Mexican Operations of Patheon for USD34 Million 22

Perrigo to Acquire Women's Healthcare Business from Lumara Health for USD82 Million 23

Perrigo Acquires OTC Products From Aspen Global For USD51 Million 25

Perrigo Company Acquires Ophthalmic Product Portfolio From Fera Pharma For Up To USD129 Million 25

Omega Pharma Acquires Arterin Business Of Pharco For USD13 Million 26

Omega Pharma Acquires Rights To Optalidon From Novartis Consumer Health 28

Omega Pharma Completes Acquisition Of Identified Non-Core OTC Brands In Europe From GSK For USD614 Million 28

Venture Financing 30

Proteostasis Therapeutics Raises USD37 Million in Series B Financing 30

Proteostasis Therapeutics Raises USD22 Million in Venture Financing 31

Proteostasis Therapeutics Raises Additional USD2 Million in Venture Financing 32

Proteostasis Therapeutics Raises USD3 Million in Venture Financing 33

Proteostasis Therapeutics Raises USD71 Million In Series A Financing 33

Partnerships 34

Dompe Farmaceutici Enters into Distribution Agreement with Omega Pharma 34

Paragon BioTeck Enters into Co-Promotion Agreement with Perrigo 35

NovaMedica Enters into Co-Marketing Agreement with Omega Pharma 36

Proteostasis Therapeutics Amends Research Agreement with Astellas Pharma 37

Proteostasis Therapeutics Extends Co-Development Agreement With Cystic Fibrosis Foundation Therapeutics 38

Perrigo Amends Development And Commercialization Agreement With Transition Therapeutics For ELND005 39

Teva Pharma Enters Into Agreement With Perrigo For Generic Temozolomide 40

Impax Labs Enters Into Co-Development Agreement With Perrigo 41

Omega Pharma Enters Into Co-Marketing Agreement With Kwizda Pharma For BronchoStop Cough Products 42

Omega Pharma Enters Into Joint Venture With Cavi Brands To Form OmegaLabs 42

Proteostasis Therapeutics Enters Into Co-Development Agreement With Scripps Research Institute 43

Proteostasis Therapeutics Enters into Co-Development Agreement with Cystic Fibrosis Foundation Therapeutics 44

Omega Pharma Enters Into Co-Development Agreement With Sienna Biotec 45

Meda Enters Into Co-Marketing Agreement With Omega Pharma For SB12 46

Oncogenerix Enters into Distribution Agreement with Rosemont Pharma for Soltamox 46

Proteostasis Therapeutics Enters Into Co-Development Agreement With Elan 47

Licensing Agreements 48

TLC Therapeutics Enters into Licensing Agreement with Rosemont Pharma 48

Perrigo Enters Into Licensing Agreement With Fera Pharma For Neptazane 49

Proteostasis Therapeutics Amends its Licensing Agreement With Harvard University 49

Perrigo Enters into Licensing Agreement with Highland Pharma 51

Perrigo Enters into Licensing Agreement with Flamel Ireland 51

BioLineRx Enters into Licensing Agreement with Omega Pharma for BL-5010 52

Perrigo Enters into Licensing Agreement with Imago Pharma 53

Zogenix Amends Agreement with Elan Pharma 54

Perrigo Enters Into Licensing Agreement With Brilite Nutritionals 55

Equity Offering 56

Proteostasis Therapeutics Raises USD65 Million in Public Offering of Shares 56

Perrigo Raises USD1.03 Billion in Public Offering of Shares 57

Omega Pharma Completes Public Offering Of Shares For USD237 Million 59

Debt Offering 60

Perrigo Raises USD700 Million in Public Offering of 4.375% Notes Due 2026 60

Perrigo Raises USD500 Million in Public Offering of 3.5% Notes Due 2021 61

Perrigo Raises USD400 Million in Public Offering of 4.9% Senior Notes Due 2044 62

Perrigo Raises USD500 Million in Public Offering of 3.5% Senior Notes Due 2021 64

Perrigo Raises USD700 Million in Public Offering of 3.9% Senior Notes Due 2024 65

Perrigo Completes Private Placement Of Notes Due 2023 For USD800 Million 67

Perrigo Completes Private Placement Of Notes Due 2043 For USD400 Million 67

Perrigo Completes Private Placement Of Notes Due 2018 For USD600 Million 68

Perrigo Completes Private Placement Of Notes Due 2016 For USD500 Million 69

Omega Pharma Completes Public Offering Of Bonds Due 2017 For USD383 Million 70

Omega Pharma Completes Public Offering Of Bonds Due 2017 For USD237.6 Million 71

Omega Pharma Completes Public Offering Of Bonds Due 2019 For USD158.4 Million 72

Perrigo Completes Private Placement Of Notes Due 2023 For USD175 Million 73

Perrigo Completes Private Placement Of Series 2011-A Senior Notes Due 2021 For USD75 Million 74

Perrigo Completes Private Placement Of Series 2011-C Senior Notes Due 2026 For USD100 Million 74

Asset Transactions 75

Royalty Pharma Acquires Royalty Stream of Tysabri from Perrigo for USD2.85 Billion 75

Custopharm Acquires Two ANDA Pharmaceutical Products from Perrigo 76

IDT Australia to Acquire Synthetic Conjugated Estrogens from Perrigo 77

Medline Industries Acquires Personal Hygiene Business Assets From Perrigo 78

Watson Pharma Acquires Generic Pharma Products From Perrigo 79

Acquisition 80

Strides Shasun Acquires Perrigo API India from Perrigo for USD14.8 Million 80

Perrigo Company Acquires Banner Pharmacaps from Patheon for USD36.4 Million 81

Perrigo Acquires Omega Pharma for USD4.76 Billion 82

Ind-Swift Lab May Sell Stake in Company 83

Perrigo Acquires Remaining 15% Stake in Vedants Drugs & Fine Chemicals 84

Perrigo To Acquire 7% Stake In Transition Therapeutics For USD15 Million 85

Perrigo Completes Acquisition Of Elan For USD8.6 Billion 86

Perrigo Acquires Rosemont Pharma From Close Brothers Private Equity For USD284 Million 88

Omega Pharma Acquires Naturoteek 90

Perrigo Acquires Remaining 81.5% Stake In Cobrek Pharma For USD45 Million 90

Couckinvest Completes Acquisition Of Remaining Stake In Omega Pharma For USD1.26 Billion 91

Perrigo Acquires CanAm Care, Distributor Of Diabetes Care Products, For USD36 Million 92

Perrigo Completes Acquisition Of Paddock Labs 93

Perrigo Company Plc-Key Competitors 96

Key Employees 97

Locations And Subsidiaries 98

Head Office 98

Other Locations & Subsidiaries 98

Recent Developments 105

Strategy And Business Planning 105

Jan 11, 2016: Perrigo Company Increases 2016 Full-Year Adjusted Earnings Per Share Guidance 105

Financial Announcements 106

May 30, 2017: Perrigo Company Files First Quarter 2017 Form 10-Q And Reports First Quarter 2017 Financial Results 106

May 22, 2017: Perrigo Reports Fourth Quarter 108

Apr 25, 2017: Perrigo Announces Select Preliminary Unaudited First Quarter 2017 Financial Results 111

Feb 27, 2017: Perrigo Company Reports Select Preliminary Unaudited Calendar Year 2016 Financial Results And Initial Calendar Year 2017 Guidance 112

Nov 10, 2016: Perrigo Company Reports Third Quarter 2016 Financial Results 114

Aug 10, 2016: Perrigo Company Reports Second Quarter 2016 Financial Results 117

May 16, 2016: Perrigo Company Reports First Quarter 2016 Financial Results 119

Feb 18, 2016: Perrigo Company Reports Record Fourth Quarter & Calendar Year Net Sales And Adjusted Net Income 121

Corporate Communications 123

Jun 05, 2017: Perrigo Announces Forthcoming Retirement Of CEO John Hendrickson 123

May 08, 2017: Perrigo Announces Two New Independent Directors 124

Feb 27, 2017: Perrigo Announces Leadership Changes 125

Nov 10, 2016: Perrigo Company Announces Appointment of Two New Independent Directors to Board 126

Apr 25, 2016: Perrigo Appoints John T. Hendrickson as Chief Executive Officer, Provides Preliminary First Quarter 2016 Selected Financial Results, and Updates Full Year 2016 Guidance 127

Feb 19, 2016: Perrigo Furthers Commitment to Ireland 129

Product News 130

Jun 19, 2017: Perrigo Announces the Launch of Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution 130

Apr 12, 2016: Perrigo Announces First-to-Market Launch of the OTC Store Brand Equivalent to Glucerna Aseptic Adult Nutritional Shake 131

Mar 08, 2017: Perrigo Announces First-To-Market Launch Of The OTC Store Brand Equivalent To Women's Rogaine Foam 132

Feb 17, 2017: Perrigo Announces FDA Final Approval For Hydrocodone Bitartrate And Homatropine Methylbromide Oral Solution 133

Other Significant Developments 134

Jan 10, 2017: Perrigo Updates Segment Reporting Structure 134

Dec 08, 2016: Perrigo Announces Portfolio Review Developments And Intention To Restructure Branded Consumer Healthcare's Belgium Business 135

Appendix 136

Methodology 136

About GlobalData 136

Contact Us 136

Disclaimer 136

List of Figures

Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8

Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 9

Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10

Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 11

Perrigo Company Plc, Medical Devices Deals, 2011 to YTD 2017 13

List of Tables

Perrigo Company Plc, Pharmaceuticals & Healthcare, Key Facts, 2016 1

Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8

Perrigo Company Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9

Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10

Perrigo Company Plc, Deals By Therapy Area, 2011 to YTD 2017 11

Perrigo Company Plc, Medical Devices Deals, 2011 to YTD 2017 13

Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 14

Perrigo Acquires Generic Dosage Forms of Retin-A from Matawan Pharma 19

Perrigo Acquires US Rights to Entocort from AstraZeneca for USD380 Million 19

Perrigo Acquires ScarAway Brand from Enaltus 20

Perrigo Acquires OTC Brands Portfolio from GlaxoSmithKline Consumer Healthcare for USD226 Million 21

Perrigo Acquires Mexican Operations of Patheon for USD34 Million 22

Perrigo to Acquire Women's Healthcare Business from Lumara Health for USD82 Million 23

Perrigo Acquires OTC Products From Aspen Global For USD51 Million 25

Perrigo Company Acquires Ophthalmic Product Portfolio From Fera Pharma For Up To USD129 Million 25

Omega Pharma Acquires Arterin Business Of Pharco For USD13 Million 26

Omega Pharma Acquires Rights To Optalidon From Novartis Consumer Health 28

Omega Pharma Completes Acquisition Of Identified Non-Core OTC Brands In Europe From GSK For USD614 Million 28

Proteostasis Therapeutics Raises USD37 Million in Series B Financing 30

Proteostasis Therapeutics Raises USD22 Million in Venture Financing 31

Proteostasis Therapeutics Raises Additional USD2 Million in Venture Financing 32

Proteostasis Therapeutics Raises USD3 Million in Venture Financing 33

Proteostasis Therapeutics Raises USD71 Million In Series A Financing 33

Dompe Farmaceutici Enters into Distribution Agreement with Omega Pharma 34

Paragon BioTeck Enters into Co-Promotion Agreement with Perrigo 35

NovaMedica Enters into Co-Marketing Agreement with Omega Pharma 36

Proteostasis Therapeutics Amends Research Agreement with Astellas Pharma 37

Proteostasis Therapeutics Extends Co-Development Agreement With Cystic Fibrosis Foundation Therapeutics 38

Perrigo Amends Development And Commercialization Agreement With Transition Therapeutics For ELND005 39

Teva Pharma Enters Into Agreement With Perrigo For Generic Temozolomide 40

Impax Labs Enters Into Co-Development Agreement With Perrigo 41

Omega Pharma Enters Into Co-Marketing Agreement With Kwizda Pharma For BronchoStop Cough Products 42

Omega Pharma Enters Into Joint Venture With Cavi Brands To Form OmegaLabs 42

Proteostasis Therapeutics Enters Into Co-Development Agreement With Scripps Research Institute 43

Proteostasis Therapeutics Enters into Co-Development Agreement with Cystic Fibrosis Foundation Therapeutics 44

Omega Pharma Enters Into Co-Development Agreement With Sienna Biotec 45

Meda Enters Into Co-Marketing Agreement With Omega Pharma For SB12 46

Oncogenerix Enters into Distribution Agreement with Rosemont Pharma for Soltamox 46

Proteostasis Therapeutics Enters Into Co-Development Agreement With Elan 47

TLC Therapeutics Enters into Licensing Agreement with Rosemont Pharma 48

Perrigo Enters Into Licensing Agreement With Fera Pharma For Neptazane 49

Proteostasis Therapeutics Amends its Licensing Agreement With Harvard University 49

Perrigo Enters into Licensing Agreement with Highland Pharma 51

Perrigo Enters into Licensing Agreement with Flamel Ireland 51

BioLineRx Enters into Licensing Agreement with Omega Pharma for BL-5010 52

Perrigo Enters into Licensing Agreement with Imago Pharma 53

Zogenix Amends Agreement with Elan Pharma 54

Perrigo Enters Into Licensing Agreement With Brilite Nutritionals 55

Proteostasis Therapeutics Raises USD65 Million in Public Offering of Shares 56

Perrigo Raises USD1.03 Billion in Public Offering of Shares 57

Omega Pharma Completes Public Offering Of Shares For USD237 Million 59

Perrigo Raises USD700 Million in Public Offering of 4.375% Notes Due 2026 60

Perrigo Raises USD500 Million in Public Offering of 3.5% Notes Due 2021 61

Perrigo Raises USD400 Million in Public Offering of 4.9% Senior Notes Due 2044 62

Perrigo Raises USD500 Million in Public Offering of 3.5% Senior Notes Due 2021 64

Perrigo Raises USD700 Million in Public Offering of 3.9% Senior Notes Due 2024 65

Perrigo Completes Private Placement Of Notes Due 2023 For USD800 Million 67

Perrigo Completes Private Placement Of Notes Due 2043 For USD400 Million 67

Perrigo Completes Private Placement Of Notes Due 2018 For USD600 Million 68

Perrigo Completes Private Placement Of Notes Due 2016 For USD500 Million 69

Omega Pharma Completes Public Offering Of Bonds Due 2017 For USD383 Million 70

Omega Pharma Completes Public Offering Of Bonds Due 2017 For USD237.6 Million 71

Omega Pharma Completes Public Offering Of Bonds Due 2019 For USD158.4 Million 72

Perrigo Completes Private Placement Of Notes Due 2023 For USD175 Million 73

Perrigo Completes Private Placement Of Series 2011-A Senior Notes Due 2021 For USD75 Million 74

Perrigo Completes Private Placement Of Series 2011-C Senior Notes Due 2026 For USD100 Million 74

Royalty Pharma Acquires Royalty Stream of Tysabri from Perrigo for USD2.85 Billion 75

Custopharm Acquires Two ANDA Pharmaceutical Products from Perrigo 76

IDT Australia to Acquire Synthetic Conjugated Estrogens from Perrigo 77

Medline Industries Acquires Personal Hygiene Business Assets From Perrigo 78

Watson Pharma Acquires Generic Pharma Products From Perrigo 79

Strides Shasun Acquires Perrigo API India from Perrigo for USD14.8 Million 80

Perrigo Company Acquires Banner Pharmacaps from Patheon for USD36.4 Million 81

Perrigo Acquires Omega Pharma for USD4.76 Billion 82

Ind-Swift Lab May Sell Stake in Company 83

Perrigo Acquires Remaining 15% Stake in Vedants Drugs & Fine Chemicals 84

Perrigo To Acquire 7% Stake In Transition Therapeutics For USD15 Million 85

Perrigo Completes Acquisition Of Elan For USD8.6 Billion 86

Perrigo Acquires Rosemont Pharma From Close Brothers Private Equity For USD284 Million 88

Omega Pharma Acquires Naturoteek 90

Perrigo Acquires Remaining 81.5% Stake In Cobrek Pharma For USD45 Million 90

Couckinvest Completes Acquisition Of Remaining Stake In Omega Pharma For USD1.26 Billion 91

Perrigo Acquires CanAm Care, Distributor Of Diabetes Care Products, For USD36 Million 92

Perrigo Completes Acquisition Of Paddock Labs 93

Perrigo Company Plc, Key Competitors 96

Perrigo Company Plc, Key Employees 97

Perrigo Company Plc, Subsidiaries 98

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Perrigo Company Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.


Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com